Research Article
The Role of Xuefu Zhuyu Decoction in Prevention of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention
Table 1
General characteristics and relative clinical and biochemical variables.
| | | Group A (n = 126) | Group B (n = 130) | value |
| | Age (years) | 60 ± 9 | 59 ± 9 | 0.52 | | Male (n) | 71 (56%) | 78 (60%) | 0.55 | | Height (meter) | 1.64 ± 0.09 | 1.63 ± 0.09 | 0.81 | | Weight (kg) | 67 ± 10 | 68 ± 10 | 0.41 | | LVEF (%) | 60 ± 10 | 58 ± 12 | 0.31 | | HF (n) | 24 (19%) | 28 (22%) | 0.62 | | Hypertension (n) | 68 (54%) | 71 (55%) | 0.92 | | Diabetes (n) | 24 (18%) | 25 (20%) | 0.97 | | Smoking (n) | 47 (37%) | 41 (32%) | 0.33 |
| | Clinical presents | | Previous MI (n) | 12 (10%) | 11 (8%) | 0.77 | | Multivessel disease | 12 (10%) | 14 (11%) | 0.74 | | Contrast volume (ml) | 31.39 ± 9.86 | 32.55 ± 9.67 | 0.35 |
| | Lab variables at baseline | | eGFR (ml/min 1.73 m2) | 82.58 ± 14.80 | 82.37 ± 15.56 | 0.91 | | SCr (µmol/l) | 75.62 ± 5.29 | 76.34 ± 6.60 | 0.34 | | SOD (U/ml) | 153.36 ± 7.82 | 152.27 ± 7.30 | 0.25 | | MDA (nmol/ml) | 5.11 ± 0.73 | 5.06 ± 0.51 | 0.53 |
|
|
Group A: control group; Group B: intervention group; LVEF: left ventricular ejection fraction; HF: heart failure; MI: myocardial infarction; eGFR: estimated glomerular filtration rate; SCr: serum creatinine; SOD: superoxide dismutase; MDA: malondialdehyde; LVEF:left ventricular ejection fraction; HF:heart failure.
|
